<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT944-329</title>
	</head>
	<body>
		<main>
			<p>941229 FT  29 DEC 94 / International Capital Markets: Australian drugs group in US marketing deal FH Faulding, the Australian pharmaceutical group, said Bristol-Myers Squibb, the US drugs company, has agreed to acquire exclusive US marketing rights for Faulding's new oral sustained-release morphine product, writes Nikki Tait in Sydney. The drug, patented by Faulding, will be marketed in the US under the Kadian trade name. The Australian company said it expected to file for approvals from the US Food and Drug Administration by the end of June, and to launch the product in 1996.</p>
		</main>
</body></html>
            